Emphasis
The emphasis is on engineering of targeting and responsive molecular probes of high sensitivity and specificity for PET and SPECT (radiotracers), MR (T1, T2, CEST, hyperpolarized agents), EPR, CT, optical (fluorescent and bioluminescent probes), ultrasound (microbubbles) and photoacoustic imaging. The imaging agents may be based on nano- and micro-particles, liposomes, dendrimers, proteins, small organic and inorganic molecules etc., and detectable by one or more imaging modalities. Imaging agent development through methodologies such as chemical synthesis, biological mutagenesis, microfabrication, etc., may be pursued with an intent of leading to in vivo biomedical application.
Outcome
The goal of this program is to generate robust molecular probes, imaging agents and platforms for biomedical application across all disease areas to facilitate diagnostics and improve understanding of disease state, progression, and therapeutic response.
Additional emphasis
This program also supports the development of other imaging agents, for example:
- multimodal molecular probes (PET/MRI, PET/fluorescent, etc.)
- imaging reporter genes and reporter gene/imaging probe duos
- molecular probes as part of theranostic systems or biosensors
- imaging agents for cell labelling and in vivo tracking
- molecular probes for image-guided interventions
Note
The following related scientific areas are supported by other NIBIB programs:
- development of biomaterials is supported by the Biomaterials and Biomolecular Constructs program
- synthetic biology approaches are supported by the Synthetic Biology for Technology Development program
- development of associated imaging methods and related hardware/software is supported by NIBIB programs for specific imaging modalities
- image processing technology is supported by the Image Processing, Visualization, Perception and Display
Related News
NIBIB-supported researchers have developed a smart nanoprobe designed to infiltrate prostate tumors and send back a signal using an optical imaging technique known as Raman spectroscopy. The new probe, evaluated in mice, has the potential to determine tumor aggressiveness and could also enable sequential monitoring of tumors during therapy to quickly determine if a treatment strategy is working.
To provide better diagnosis and treatment of chronic liver diseases, researchers are working to use non-invasive MRI to detect and quantify liver fibrosis throughout the entire organ, which would enable earlier detection and the ability to monitor disease progression as well as the effects of treatment over time.
An automated tool captures circulating tumor cells in children with central nervous system cancers. The tool could make it easier to identify tumors that don't respond to treatment.
International effort to improve the resolution of magnetic resonance imaging (MRI) for studying the human brain has led to an ultra-high resolution 7 Tesla scanner.
NIH Blueprint MedTech program has issued nine awards in its first competition cycle. The program seeks to accelerate transformative medical devices to treat disorders of the nervous system.